Infliximab is a tumour necrosis factor (TNF)-alpha blocking drug classified as a biological response modifier. It has been suggested that the risk of malignancies, especially lymphomas, is increased in patients with rheumatoid arthritis (RA) treated with anti-TNF-alpha antibody therapy. We present a case of malignant lymphoma during the treatment of RA with infliximab and methotrexate.
机构:
Saitama Med Univ, Int Med Ctr, Ctr Comprehens Canc, Dept Hematol, Saitama, JapanSaitama Med Univ, Int Med Ctr, Ctr Comprehens Canc, Dept Hematol, Saitama, Japan
Niitsu, Nozomi
Okamoto, Masataka
论文数: 0引用数: 0
h-index: 0
机构:
Fujita Hlth Univ, Sch Med, Div Hematol & Med Oncol, Dept Internal Med, Toyoake, Aichi 47011, JapanSaitama Med Univ, Int Med Ctr, Ctr Comprehens Canc, Dept Hematol, Saitama, Japan
Okamoto, Masataka
Nakamine, Hirokazu
论文数: 0引用数: 0
h-index: 0
机构:
Kansai Univ Hlth Sci, Osaka, JapanSaitama Med Univ, Int Med Ctr, Ctr Comprehens Canc, Dept Hematol, Saitama, Japan
Nakamine, Hirokazu
Hirano, Masami
论文数: 0引用数: 0
h-index: 0
机构:
Fujita Hlth Univ, Sch Med, Div Hematol & Med Oncol, Dept Internal Med, Toyoake, Aichi 47011, JapanSaitama Med Univ, Int Med Ctr, Ctr Comprehens Canc, Dept Hematol, Saitama, Japan